Shareholders approve 9.7M share stock plan amendment, re-elect all eight directors

LIGAND PHARMACEUTICALS INC

All eight director nominees re-elected to one-year terms; votes for ranged from 12.3M to 15.3M.
Ratification of Ernst & Young as independent auditor for FY2024 approved (15.9M for, 0.8M against).
Non-binding advisory say-on-pay resolution approved with 14.3M votes for.
Restated 2002 Stock Incentive Plan approved, authorizing up to 9,713,754 common shares.
Company will cease granting awards under the 2022 Employment Inducement Plan after meeting date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.